In summary, the study could highlight the importance of Itpkb in regulating acute and chronic GvHD and delivered promising data indicating that pharmacological inhibition of Itpkb could be a potential novel therapeutic approach to control GvHD without impairing anti-leukemia immunity (149). The gene discussed is ITPKB; the disease is graft versus host disease.